A lot will change in the next 10 years, but our need for innovative medicines is unlikely to be one of them. That's one thing that makes some biotech companies exciting long-term investment opportunities, at least highly innovative ones that look well-positioned to deliver solid clinical and regulatory progress over long periods.

Let's consider one company that might have what it takes: Sarepta Therapeutics (NASDAQ: SRPT). The biotech has performed well so far this year, and it could maintain that momentum for a while. Let's find out why.

Sarepta Therapeutics' strong performance on the stock market this year reflects the fact that investors expect it to earn a crucial approval from the U.S. Food and Drug Administration (FDA). But first, some background information.

Continue reading

Source Fool.com